Literature DB >> 34780933

Systematic interaction of plasma albumin with the efficacy of chemotherapeutic drugs.

Liuchunyang Yu1, Zhenglai Hua1, Xinyi Luo1, Ting Zhao1, Yuanyan Liu2.   

Abstract

Albumin, as the most abundant plasma protein, plays an integral role in the transport of a variety of exogenous and endogenous ligands in the bloodstream and extravascular spaces. For exogenous drugs, especially chemotherapeutic drugs, binding to and being delivered by albumin can significantly affect their efficacy. Meanwhile, albumin can also bind to many endogenous ligands, such as fatty acids, with important physiological significance that can affect tumor proliferation and metabolism. In this review, we summarize how albumin with unique properties affects chemotherapeutic drugs efficacy from the aspects of drug outcome in blood, toxicity, tumor accumulation and direct or indirect interactions with fatty acids, plus application of albumin-based carriers for anti-tumor drug delivery.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Albumin; Chemotherapeutic drugs; Drug carrier; Drug efficacy; Fatty acids; Tumor accumulation

Mesh:

Substances:

Year:  2021        PMID: 34780933     DOI: 10.1016/j.bbcan.2021.188655

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  2 in total

1.  Preclinical Therapeutic Assessment of a New Chemotherapeutics [Dichloro(4,4'-Bis(2,2,3,3-Tetrafluoropropoxy) Methyl)-2,2'-Bipryridine) Platinum] in an Orthotopic Patient-Derived Xenograft Model of Triple-Negative Breast Cancers.

Authors:  Tzu-Chun Kan; Mei-Hsiang Lin; Chun-Chia Cheng; Jeng-Wei Lu; Ming-Thau Sheu; Yuan-Soon Ho; Sri Rahayu; Jungshan Chang
Journal:  Pharmaceutics       Date:  2022-04-11       Impact factor: 6.525

2.  Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy.

Authors:  Chengliang Yuan; Meifang Huang; Huilin Wang; Wei Jiang; Cuiyun Su; Shaozhang Zhou
Journal:  Cancer Manag Res       Date:  2022-01-26       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.